Vera Therapeutics (VERA) Interest Expenses (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Interest Expenses data on file, last reported at $1.8 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 1.73% year-over-year to $1.8 million; the trailing twelve-month figure through Mar 2026 stood at $7.6 million (up 0.67% YoY), and the FY2025 full-year result was $7.5 million, down 1.25% from the prior year.
• Interest Expenses for Q1 2026 stood at $1.8 million, down from $1.9 million in the prior quarter.
• Across five years, Interest Expenses topped out at $2.0 million in Q3 2025 and bottomed at $118000.0 in Q1 2022.
• The 5-year median for Interest Expenses is $1.8 million (2025), against an average of $1.3 million.
• The widest annual swing landed in 2022, when Interest Expenses soared 2895.0%; it then decreased 5.98% in 2025.
• A 5-year view of Interest Expenses shows it stood at $599000.0 in 2022, then surged by 76.29% to $1.1 million in 2023, then soared by 77.18% to $1.9 million in 2024, then gained by 1.76% to $1.9 million in 2025, then slipped by 4.25% to $1.8 million in 2026.
• The last three Interest Expenses figures came in at $1.8 million (Q1 2026), $1.9 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.

Peer Comparison